Literature DB >> 17115339

Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm.

Elizabeth M Murphy1, Rosemary Sexton, Brendan J Moran.   

Abstract

PURPOSE: Epithelial appendiceal tumors are uncommon but can present as an emergency simulating appendicitis, or unexpectedly at laparotomy, laparoscopy, or on cross-sectional imaging. Occult rupture with features of pseudomyxoma peritonei may be encountered. We report the operative findings, pathologic assessment, and early outcomes in 123 consecutive patients with a perforated appendiceal neoplasm presenting as pseudomyxoma peritonei.
METHODS: From March 1994 to March 2004, 292 patients were referred to a peritoneal malignancy surgical treatment center. Complete tumor removal (cytoreduction) was attempted in selected patients and, if achieved, surgery was combined with intraoperative, intraperitoneal mitomycin C (10 mg/m(2)).
RESULTS: In total, 123 patients (52 males; 41 percent) underwent laparotomy for a perforated appendiceal malignancy presenting as pseudomyxoma peritonei. The median age was 52 (range 30-77) years. Complete cytoreduction was achieved in 83 of 123 patients (67 percent), major palliative resection in 34 patients (28 percent), and 6 patients (5 percent) were inoperable. Postoperative mortality was 6 of 123 patients (5 percent). Kaplan-Meier analysis of the 83 patients who had complete tumor removal predicted 75 percent disease-free survival at five years.
CONCLUSIONS: A perforated appendiceal epithelial tumor most frequently presents as pseudomyxoma peritonei. This treatment strategy, involving surgery and intraperitoneal chemotherapy, can result in good outcomes in this rare and otherwise fatal disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17115339     DOI: 10.1007/s10350-006-0741-9

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  17 in total

1.  Pseudomyxoma peritonei.

Authors:  Katharine E Bevan; Faheez Mohamed; Brendan J Moran
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

Review 2.  Management of peritoneal carcinomatosis from colorectal cancer.

Authors:  Chukwuemeka U Ihemelandu; Perry Shen; John H Stewart; Konstantinos Votanopoulos; Edward A Levine
Journal:  Semin Oncol       Date:  2011-08       Impact factor: 4.929

Review 3.  Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.

Authors:  Csilla Hasovits; Stephen Clarke
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

4.  Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: The University of Arizona early experience.

Authors:  Ioannis T Konstantinidis; Christine Young; Vassiliki L Tsikitis; Ellyn Lee; Tun Jie; Evan S Ong
Journal:  World J Gastrointest Surg       Date:  2012-06-27

5.  Efficacy of a novel mucolytic agent on pseudomyxoma peritonei mucin, with potential for treatment through peritoneal catheters.

Authors:  Javed Akhter; Krishna Pillai; Terence C Chua; Naeef Alzarin; David Lawson Morris
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

Review 6.  Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy.

Authors:  Thomas Winder; Heinz-Josef Lenz
Journal:  Oncologist       Date:  2010-07-23

7.  Pathophysiology and biology of peritoneal carcinomatosis.

Authors:  Shigeki Kusamura; Dario Baratti; Nadia Zaffaroni; Raffaella Villa; Barbara Laterza; Maria Rosaria Balestra; Marcello Deraco
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

8.  A new standard of care for the management of peritoneal surface malignancy.

Authors:  F Mohamed; T Cecil; B Moran; P Sugarbaker
Journal:  Curr Oncol       Date:  2011-04       Impact factor: 3.677

9.  Pseudomyxoma peritonei secondary to epithelial appendicular neoplasms. Experience in a non-specialised centre.

Authors:  J Ruiz-Tovar; V Morales Castiñeiras; D García Teruel; A Sanjuanbenito Dehesa; E Lobo Martínez; E Martínez Molina
Journal:  Clin Transl Oncol       Date:  2007-11       Impact factor: 3.405

10.  Assessment of a novel mucolytic solution for dissolving mucus in pseudomyxoma peritonei: an ex vivo and in vitro study.

Authors:  Krishna Pillai; Javed Akhter; David L Morris
Journal:  Pleura Peritoneum       Date:  2017-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.